| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (P.H.G., I.B.K., M.P., H.M., L.P.R.), Biostatistics (B.C.), and Pathology (A.P.H.), Columbia University, New York, NY.
Address correspondence and reprint requests to Dr. Paul H. Gordon, Eleanor and Lou Gehrig MDA/ALS Research Center, Neurological Institute, Box 107, 710 West 168th Street, New York, NY 10032; e-mail: PHG8{at}columbia.edu
Objective: To define the syndrome of primary lateral sclerosis (PLS) and disorders that contain features of both ALS and PLS, to determine the time beyond which PLS is less likely to become ALS clinically, and to determine the outcome of people with PLS and those who develop lower motor neuron (LMN) signs.
Methods: The authors reviewed the records of all 39 patients initially diagnosed with PLS in 1984 to 2004. Diagnostic subgroups were defined based on clinical features. The authors used Kaplan-Meier methods to estimate the time to diagnosis, linear regression analyses to assess function, and a Cox proportional hazard model to assess survival in subgroups.
Results: Of the 39 patients, 29 had only upper motor neuron (UMN) signs on initial evaluation. Thirteen of the 29 were later classified as having UMN-dominant ALS (UMN-D) because they acquired evidence of denervation by EMG (3.17 years) or examination (3.67 years). Sixteen of the 29 patients, classified as clinically pure PLS, retained only UMN signs and a normal EMG (mean follow-up 8.7 years). Ten patients who met criteria for ALS at the initial visit were used as controls. The UMN-dominant ALS group had lower functional scores (p = 0.033) than the PLS group, and similar scores to those with ALS. Survival was longer in both the PLS group (p = 0.027) and the UMN-D group (p = 0.067) than the ALS group.
Conclusions: Clinically pure PLS can be defined by isolated UMN signs 4 years after symptom onset, and is a syndrome of slow progression with high levels of function. Prior to the fourth year, the diagnosis of PLS cannot be made with certainty because many patients develop LMN signs. UMN-dominant ALS, defined by predominantly UMN disease with minor LMN signs, has disability similar to ALS, but slower progression.
Editorial, see page 624
Supported by NIH RO1 NS4167201 and the MDA Wings Over Wall Street, Charles and Jo Ann Tobias, and Donna Dake Funds.
Disclosure: The authors report no conflicts of interest.
Received March 8, 2005. Accepted in final form November 7, 2005.
Related articles in Neurology:
This article has been cited by other articles:
|
|
 |
|
  S H Wong, M Boggild, T P Enevoldson, and N A Fletcher Myelopathy but normal MRI: where next? Practical Neurology, April 1, 2008; 8(2): 90 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Zoccolella, E Beghi, G Palagano, A Fraddosio, V Guerra, V Samarelli, V Lepore, I L Simone, P Lamberti, L Serlenga, et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study J. Neurol. Neurosurg. Psychiatry, January 1, 2008; 79(1): 33 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Mitsumoto, A. M. Ulug, S. L. Pullman, C. L. Gooch, S. Chan, M. -X. Tang, X. Mao, A. P. Hays, A. G. Floyd, V. Battista, et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS Neurology, April 24, 2007; 68(17): 1402 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Tartaglia, A. Rowe, K. Findlater, J. B. Orange, G. Grace, and M. J. Strong Differentiation Between Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis: Examination of Symptoms and Signs at Disease Onset and During Follow-up Arch Neurol, February 1, 2007; 64(2): 232 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rosenfeld and M. Swash What's in a name?: Lumping or splitting ALS, PLS, PMA, and the other motor neuron diseases Neurology, March 14, 2006; 66(5): 624 - 625. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
